Abstract:BackgroundThe Mount Sinai Hospital recently implemented a comprehensive organ donor testing program to service the clinical needs of transplant services in the New York City metro area. Conventional serology testing is not approved by the FDA for donor testing. To support this program, the MSH Chemistry Laboratory implemented and validated a comprehensive donor testing panel on the Abbott Alinity S donor testing platform. We validated donor serology testing for the following assays: HIV-1/2 (HIV), Anti-Hepatitis B Core (Anti-HBc), Hepatitis B Surface Antigen (HBsAg), Human T-lymphotropic virus I and II (HTLV-I/II), Anti-Hepatitis C (Anti-HCV), and Trypanosoma cruzi antibodies (T.Cruzi). The Alinity S System is an automated immunoassay-based analyzer FDA-approved for donor testing. The analyzer consists of two distinct sample 'paths' and is effectively two instruments combined in one analyzer. The analyzer is approved for use in living donor serum and plasma and in cadaveric serum. Prior to going live, we found that there was limited guidance on laboratory quality assurance programs related to donor testing. In addition to confirming assay analytical performance, we designed and implemented a comprehensive quality assurance program prior to satisfy compliance with regulatory guidelines, addressing proficiency compliance, sample TAT, and control ranges, amongst other quality indicators.MethodsInter and Intraday precision was assessed through replicate analysis of positive and negative controls, where 10 replicates of both controls were assayed on a single day, and one replicate of each control was assayed daily for 7 distinct days, results were represented as %CV. Result accuracy was assessed through split sample analysis of known serologically positive (n=20) and negative samples (n=40). Each sample was assayed on two distinct lots of reagents, each with its own unique calibration curve. Accuracy was confirmed in both living donor (n=30), and cadaveric samples (n=10). In addition, split sample analysis was performed between the Alinity S and FDA-approved donor testing assays in a reference laboratory (N=7). A carryover study was performed through the analysis of triplicate replicates of low, high, and then low controls. These analyses were performed for all 6 assays.ResultsIntraday precision using assay general controls afforded the following %CV: HIV: 3.1%, 6.5%; Anti-HBc: 1.3%, 2.6%; Anti-HCV: 3.3%, 11.7%; HTLV-I,II: 2.5%, 5.9%; T.Cruzi: 2.8%, 0%; HBsAg: 3.2%, 11.6%. Interday precision yielded the following in %CV: HIV: 2.9%, 10.0%; Anti-HBc: 3.0%, 5.6%; Anti-HCV: 3.3%, 3.4%; HTLV-I,II: 2.8%, 4.6%; T.Cruzi: 2.4%, 0%; HBsAg: 4.7%, 7.8%. Accuracy studies yielded 100% positive and negative correlation for all 6 assays in both living donor and cadaveric samples. In addition, there was a 100% serological correlation for samples compared to reference laboratories. Carryover studies showed no evidence of sample carryover.ConclusionsThe Abbott Alinity S shows acceptable assay precision on all 6 validated assays. The assays are serologically accurate in both cadaveric and living donor samples. As such, the assays and platform are acceptable for use in donor screening. We designed a unique quality assurance program including a comprehensive self-proficiency and instrument crosscheck program to ensure analyzer accuracy, as well as adherence to regulatory guidelines.

A-065 The CDC HoSt Certification Requirements Have Been Met for More Than Four Years by the Atellica IM, ADVIA Centaur Testosterone II and Dimension Vista LOCI Total Testosterone Immunoassays

A-032 Accuracy of Immunoassay Testosterone Assays in Low Testosterone Patients

Improving the Diagnosis, Treatment, and Prevention of Endocrine Diseases Through Accurate and Reliable Laboratory Measurements With CDC Clinical Standardization Programs

A-030 Evaluation of the Analytical Performance of Two Reproductive Endocrinology Related Assays on the Atellica CI Analyzer

A-003 Beckman Coulter DxI 9000 Immunoassay Analyzer's High Sensitivity Troponin I achieves >90% six sigma performance when assessed against clia 2024 performance goals

A-038 Interlaboratory Comparison of Parathyroid Hormone Analytical Results Across Clinical Assays from 8 Manufacturers - Steps Towards Standardization

A-078 Harmonization of Immunoassay Reference Intervals with LC-MS/MS for Total and Calculated Free Testosterone Measurement

B-143 Using Big Data Analytics to Measure the Multi-year Consistency of Sigma Metrics for Vitros Oncology Assays

B-142 Using Big Data Analytics to Measure the Multi-year Consistency of Sigma metrics for Vitros Cardiac Assays

B-099 Validation and Clinical Implementation of Organ Procurement Serology Testing: Our Analytical and Regulatory Experience in Implementing a New Donor Testing Program

A-061 Analytical Performance and R55G Mutant Detection Ability of an Improved Thyroid-Stimulating Hormone Assay, TSH3-Ultra II, on the ADVIA Centaur Immunoassay System and the Atellica IM Analyzer

A-092 Siemens Healthineers Commitment to Quality - A Focus on Continuous Improvement and Customer Experience

Evaluation of serum electrolytes measurement through the 6-year trueness verification program in China

Longitudinal analysis of external quality assessment of immunoassay-based steroid hormone measurement indicates potential for improvement in standardization

Standardisation and harmonisation of thyroid-stimulating hormone measurements: historical, current, and future perspectives

A-008 Verification of Interchangeability of Results for High-Sensitivity Troponin (TNIH) Between Atellica Solution® and Atellica CI® Analyzers

Performance evaluation of a novel high-sensitivity cardiac troponin T assay: analytical and clinical perspectives

B-133 Beckman Coulter’s DxC 500 AU Clinical Chemistry Analyzer, Assessed by Six Sigma Metrics, Meets and Exceeds the Demands of CLIA 2024 Performance Specifications

Analytical verification of the Atellica VTLi point of care high sensitivity troponin I assay

Analytical and Clinical Performance Evaluation of a New High-Sensitivity Cardiac Troponin I Assay

A Comparison Study: Possible Bias in Troponin I Measurement Obtained with a Point of Care Testing and a Central Laboratory Analyzers Employing Different Biological Matrices and Anticoagulants